Banka BioLoo Limited has approved the issuance of a corporate guarantee to support a credit facility for its subsidiary, Megaliter Varunaa Private Limited. The guarantee covers an amount up to ₹4.35 Crores in favor of Maanaveeya Development & Finance Private Limited. This is an unconditional and irrevocable guarantee that will remain in force until the credit facility is fully repaid. While it adds to the company's contingent liabilities on a standalone basis, it has no impact on the consolidated financial statements.

• Corporate guarantee issued for subsidiary Megaliter Varunaa Private Limited for up to ₹4.35 Crores.
• Guarantee provided to lender Maanaveeya Development & Finance Private Limited to secure credit facilities.
• The guarantee is unconditional and irrevocable until the full discharge of obligations.
• Transaction is confirmed to be at arm's length with no immediate impact on consolidated financials.
• The guarantee will be treated as a contingent liability on the company's standalone balance sheet.

Banka BioLoo Limited has received formal approval from the National Stock Exchange (NSE) for the listing and trading of 29,575 equity shares. These shares were issued following the exercise of options under the company's Employee Stock Option Plan (ESOP). The shares have a face value of Rs. 10 each and will be available for trading starting January 23, 2026. This is a routine administrative update following the allotment process.

• Listing and trading approval granted for 29,575 equity shares
• Shares issued under the Employee Stock Option Plan (ESOP)
• Effective date for dealings on the exchange is January 23, 2026
• Face value of the newly listed shares is Rs. 10 per share
• Distinctive numbers for the new shares are 10892858 to 10922432

Banka BioLoo Limited has approved the allotment of 29,575 equity shares following the exercise of options under its 2023 Employee Stock Option Plan. This allotment increases the company's total paid-up equity share capital from Rs. 10.89 crore to approximately Rs. 10.92 crore. The shares were issued at an exercise price of Rs. 10 per share, which is equal to the face value. The resulting equity dilution is marginal at approximately 0.27%, representing a standard administrative corporate action.

• Allotment of 29,575 equity shares of face value Rs. 10 each
• Total paid-up capital increased to Rs. 10,92,24,320 comprising 1,09,22,432 shares
• Exercise price for the options was set at Rs. 10 per share with zero premium
• The new shares rank pari-passu in all respects with existing equity shares

Banka BioLoo Limited has filed a compliance report for the quarter ended December 31, 2025, regarding SEBI (Depositories and Participants) Regulations, 2018. The company stated that Regulation 74(5), which concerns the processing of dematerialization requests, is not applicable to them for this period. This confirmation was backed by a letter from their Registrar and Share Transfer Agent, Bigshare Services Private Limited. This is a standard administrative filing with no impact on the company's financial health or operations.

• Compliance filing submitted for the quarter ended December 31, 2025
• Regulation 74(5) of SEBI (Depositories and Participants) Regulations declared not applicable
• Confirmation received from Registrar and Share Transfer Agent, Bigshare Services Private Limited
• Official notification dated January 5, 2026, sent to the National Stock Exchange

Banka BioLoo Limited has approved the grant of 21,000 stock options to eligible employees under its 2023 ESOP scheme. Each option is convertible into one equity share of face value Rs. 10, which also serves as the exercise price. The vesting is structured over a four-year period, with 25% of the options vesting annually starting from the first anniversary of the grant. This move is intended to incentivize and retain key personnel by aligning their interests with the company's performance.

• Grant of 21,000 options convertible into 21,000 equity shares of Rs. 10 each.
• Exercise price is set at the face value of Rs. 10 per share.
• Vesting schedule follows a 4-year timeline with 25% vesting each year.
• Exercise period is limited to 2 years from the date of each vesting tranche.
• The new shares issued will rank pari passu with existing equity shares.

Banka BioLoo Limited has announced the closure of its trading window effective from January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is a standard procedure ahead of the declaration of the company's unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all directors, designated persons, and their immediate relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be communicated at a later date.

• Trading window closure begins on January 1, 2026.
• Closure pertains to the unaudited financial results for the quarter and nine months ending December 31, 2025.
• Restriction applies to all Directors, Designated Persons, and their immediate relatives.
• Window will reopen 48 hours after the financial results are officially declared.
• Board meeting date for result approval to be announced in due course.